Molecular Partners_JPM2026_CorporatePresentation_R.pdf

1、Extending the Boundaries of Targeted Cancer TherapiesPatrick Amstutz,CEOJanuary 2026 Nasdaq,SIX Swiss Exchange:MOLNDisclaimerThis presentation contains forward looking statements.Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statem

2、ents as that term is defined in the Private Securities Litigation Reform Act of 1995,as amended,including without limitation:implied and express statements regarding the clinical development of Molecular Partners current or future product candidates;expectations regarding timing for reporting data f

3、rom ongoing clinical trials or the initiation of future clinical trials;the potential therapeutic and clinical benefits of Molecular Partners product candidates and its RDT and Switch-DARPin platforms;the selection and development of future programs;Molecular Partners collaboration with Orano Med in

4、cluding the benefits and results that may be achieved through the collaboration;and Molecular Partners expected business and financial outlook,including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway.These statements may be identified by words such

5、as“aim”,anticipate,“expect”,“guidance”,“intend”,“outlook”,“plan”,“potential”,“will”and similar expressions,and are based on Molecular Partners current beliefs and expectations.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected i

6、n such statements.Some of the key factors that could cause actual results to differ from Molecular Partners expectations include,but are not limited to,those set forth in under the heading“Risk Factors”in Molecular Partners Annual Report on Form 20-F for the year ended December 31,2024 and other fil